Notice Information
Notice Title
Transfection Kit
Notice Description
The Clinical Biotechnology Centre at the NHS Blood and Transplant is an MHRA licensed facility for the manufacture of investigational medical products such as advanced therapies and biotechnology products which includes plasmid DNA, viral vectors and therapeutic proteins. The organisation intends to initiate a procurement process for the supply of advanced and cost-effective transfection reagents demonstrating optimal performance characteristics for the delivery of various nucleic acid formats into mammalian cells. In the initial phase, transfection reagents are sought for the production of lentiviral and adeno-associated viral vectors utilizing packaging cell lines, and for a range of related research and clinical applications. It is anticipated that these reagents also will be utilised for gene therapies and other therapeutic manufacturing or research purposes using DNA and RNA or other novel modalities requiring transfection. The transfection reagent of choice must demonstrate the efficient and low-cytotoxic delivery of the following non-exhaustive list modalities such as plasmid DNA, synthetic DNA, enzymatically produced DNA, RNA and any other novel modalities. The reagent must be of GMP quality and be compatible with HEK293 suspension and adherent cell culture systems for clinical grade manufacturing of gene therapy vectors. Suitability to transfect cells in process intensified cell culture system is a critical requirement along with cell culture systems that utilise high cell density cultures. Transfection reagent should be suitable to be used in scalable bioreactor systems.
Planning Information
Interested suppliers are asked to express their interest to rowena.thomas@nhsbt.nhs.uk and carley.butcher@nhsbt.nhs.uk by 5pm on Tuesday, 24th June 2025. Suppliers expressing an interest will be invited to attend an early market engagement exercise supplier meeting during the week of the 30th June 2025 (note: date subject to change). Prior to this session, interested suppliers will be provided with a draft specification of requirements and short questionnaire related to requirements. There is no guarantee that a formal procurement process will be launched as a result of this early market engagement exercise, nor that any contract(s) will be placed. No remuneration or compensation etc will be paid to organisations who take part in this early market engagement exercise. Suppliers should take part in this process only on the basis that they fully understand and accept this position.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-0544f1
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/030784-2025
- Current Stage
- Planning
- All Stages
- Planning
Procurement Classification
- Notice Type
- UK2 - Preliminary Market Engagement Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Not Specified
- Procurement Method Details
- Not specified
- Tender Suitability
- Not specified
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33696000 - Reagents and contrast media
33696300 - Chemical reagents
Notice Value(s)
- Tender Value
- £545,535 £500K-£1M
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 9 Jun 20258 months ago
- Submission Deadline
- Not specified
- Future Notice Date
- 28 Jul 2025Expired
- Award Date
- Not specified
- Contract Period
- 1 Dec 2025 - 30 Nov 2029 4-5 years
- Recurrence
- Not specified
Notice Status
- Tender Status
- Planning
- Lots Status
- Planning
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS BLOOD AND TRANSPLANT
- Contact Name
- Rowena Thomas
- Contact Email
- rowena.thomas@nhsbt.nhs.uk
- Contact Phone
- Not specified
Buyer Location
- Locality
- BRISTOL
- Postcode
- BS34 7QH
- Post Town
- Bristol
- Country
- England
-
- Major Region (ITL 1)
- TLK South West (England)
- Basic Region (ITL 2)
- TLK5 West of England
- Small Region (ITL 3)
- TLK52 Bath & North East Somerset and South Gloucestershire
- Delivery Location
- TLK11 Bristol, City of
-
- Local Authority
- South Gloucestershire
- Electoral Ward
- Filton
- Westminster Constituency
- Filton and Bradley Stoke
Further Information
Notice Documents
-
https://www.find-tender.service.gov.uk/Notice/030784-2025
9th June 2025 - Preliminary market engagement notice on Find a Tender
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-0544f1-2025-06-09T09:14:38+01:00",
"date": "2025-06-09T09:14:38+01:00",
"ocid": "ocds-h6vhtk-0544f1",
"initiationType": "tender",
"parties": [
{
"id": "GB-PPON-PDBY-6395-VWBP",
"name": "NHS Blood and Transplant",
"identifier": {
"scheme": "GB-PPON",
"id": "PDBY-6395-VWBP"
},
"address": {
"streetAddress": "500 North Bristol Park",
"locality": "Bristol",
"postalCode": "BS34 7QH",
"country": "GB",
"countryName": "United Kingdom",
"region": "UKK12"
},
"contactPoint": {
"name": "Rowena Thomas",
"email": "rowena.thomas@nhsbt.nhs.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.nhsbt.nhs.uk/",
"classifications": [
{
"scheme": "UK_CA_TYPE",
"id": "publicAuthorityCentralGovernment",
"description": "Public authority - central government"
}
]
}
}
],
"buyer": {
"id": "GB-PPON-PDBY-6395-VWBP",
"name": "NHS Blood and Transplant"
},
"planning": {
"milestones": [
{
"id": "engagement",
"type": "engagement",
"description": "Interested suppliers are asked to express their interest to rowena.thomas@nhsbt.nhs.uk and carley.butcher@nhsbt.nhs.uk by 5pm on Tuesday, 24th June 2025. Suppliers expressing an interest will be invited to attend an early market engagement exercise supplier meeting during the week of the 30th June 2025 (note: date subject to change). Prior to this session, interested suppliers will be provided with a draft specification of requirements and short questionnaire related to requirements. There is no guarantee that a formal procurement process will be launched as a result of this early market engagement exercise, nor that any contract(s) will be placed. No remuneration or compensation etc will be paid to organisations who take part in this early market engagement exercise. Suppliers should take part in this process only on the basis that they fully understand and accept this position.",
"dueDate": "2025-06-24T23:59:59+01:00",
"status": "scheduled"
}
],
"documents": [
{
"id": "030784-2025",
"documentType": "marketEngagementNotice",
"noticeType": "UK2",
"description": "Preliminary market engagement notice on Find a Tender",
"url": "https://www.find-tender.service.gov.uk/Notice/030784-2025",
"datePublished": "2025-06-09T09:14:38+01:00",
"format": "text/html"
}
]
},
"tender": {
"id": "C367516",
"legalBasis": {
"id": "2023/54",
"scheme": "UKPGA",
"uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
},
"title": "Transfection Kit",
"description": "The Clinical Biotechnology Centre at the NHS Blood and Transplant is an MHRA licensed facility for the manufacture of investigational medical products such as advanced therapies and biotechnology products which includes plasmid DNA, viral vectors and therapeutic proteins. The organisation intends to initiate a procurement process for the supply of advanced and cost-effective transfection reagents demonstrating optimal performance characteristics for the delivery of various nucleic acid formats into mammalian cells. In the initial phase, transfection reagents are sought for the production of lentiviral and adeno-associated viral vectors utilizing packaging cell lines, and for a range of related research and clinical applications. It is anticipated that these reagents also will be utilised for gene therapies and other therapeutic manufacturing or research purposes using DNA and RNA or other novel modalities requiring transfection. The transfection reagent of choice must demonstrate the efficient and low-cytotoxic delivery of the following non-exhaustive list modalities such as plasmid DNA, synthetic DNA, enzymatically produced DNA, RNA and any other novel modalities. The reagent must be of GMP quality and be compatible with HEK293 suspension and adherent cell culture systems for clinical grade manufacturing of gene therapy vectors. Suitability to transfect cells in process intensified cell culture system is a critical requirement along with cell culture systems that utilise high cell density cultures. Transfection reagent should be suitable to be used in scalable bioreactor systems.",
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33696000",
"description": "Reagents and contrast media"
},
{
"scheme": "CPV",
"id": "33696300",
"description": "Chemical reagents"
}
],
"deliveryAddresses": [
{
"region": "UKK11",
"country": "GB",
"countryName": "United Kingdom"
}
],
"relatedLot": "1"
}
],
"value": {
"amountGross": 654000,
"amount": 545535,
"currency": "GBP"
},
"mainProcurementCategory": "goods",
"aboveThreshold": true,
"lots": [
{
"id": "1",
"contractPeriod": {
"startDate": "2025-12-01T00:00:00Z",
"endDate": "2029-11-30T23:59:59Z"
},
"status": "planning"
}
],
"communication": {
"futureNoticeDate": "2025-07-28T23:59:59+01:00"
},
"status": "planning"
},
"language": "en"
}